首页> 中文学位 >TRAIL死亡受体(DR4、DR5)在胰腺癌细胞中的表达
【6h】

TRAIL死亡受体(DR4、DR5)在胰腺癌细胞中的表达

代理获取

目录

封面

声明

英文摘要

目录

引言

1 The History of Pancreatic Surgery

2 The Pancreas

3 Tumors of the Pancreas

3.1 Pathophysiology

3.2 Carcinogenesis

3.3 Molecular Biology

3.4Roleofdysfunctionalimmune system in PC-tumordevelopmentandprogression

3.5 Epidemiology

4 Apoptosis

5TRAIL and Death receptor

6Materials and Methods

6.1Tissue collection

6.2 Immunohistochemistry

6.3Immunohistochemical scoring of DR4 andDR5

7Statistical Analysis

8 Result

9 Discussion

10 Conclusion

参考文献

展开▼

摘要

Objectives:The importance of TRAILdeathreceptor expression inpancreatic carcinoma development is not known. To reveal the putative connection ofDR4and DR5receptor expression profile to thisprocess, we analyzed and compared the expression profile of TRAILdeath receptors in pancreatic tissues of patients with pancreaticcancer (PC).
  Methods:Twenty-eight PC patients wereincluded in the study. TRAILdeath receptor expression profiles were determined by immunohistochemistry.
  Result:1, the expression of DR4, DR5 next to pancreatic cancer and non-cancer cell carcinoma
  Beside all pancreatic cancer cells and non-cancer tissues were visible expression ofDR4 and DR5. And pancreatic tissue expression of DR4 and DR5 were significantly higher than the adjacent tissues (P <0.05), the difference was statistically significant. In bothorganizations, the expression of DR4 was significantly stronger than DR5 (P <0.05), the difference was statistically significant.2, DR4, expression and differentiation of pancreatic cancer staging and DR5 relationship DR4, DR5 expression and the clinical staging. The resultsshows stageI tumors DR4, DR5 expression was significantly higher than thestageII, III, IV tumors (P <0.05).In contrast,expression of DR4, DR5was decreased with decreased in degree of differentiation in tumors,but the difference was not statistically significant.
  Conclusion:Because PC is resistant to conventional treatmentmethods and exhibits high mortality rates, novel treatmentmodalities are needed to improve survival rates of PCpatients. Furthermore, there is also a necessity to discover newPC tumor markers for both diagnostic and prognostic purposes.Differential alterationofTRAIL receptorexpression profiles in PCpatients suggest that theTRAILreceptorDR4 and DR5 may play a pivotal role during pancreatic carcinomadevelopment.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号